Speaker Profile

M.D., Vice President, Chief of Digital Patient Experience, Sutter Health

Biography
Dr. Albert Chan champions the Sutter network’s transformation of web and mobile healthcare services, translating advancements in digital health into positive patient experiences and electronic workflows for clinicians. Under his leadership, Sutter implemented My Health Online, which securely connects patients to their doctor via video visits and messaging and allows users to check medical symptoms, schedule appointments online and view lab and test results. In addition to serving on the Sutter Care at Home Board, he is also a member of the American Telemedicine Association and of the American Hospital Association's Price Transparency Task Force. Dr. Chan earned his medical degree from the University of California, San Diego, and his bachelor's degree in biological sciences from Stanford University. He completed his residency in family medicine at the San Jose Medical Center Family Practice Residency, affiliated with Stanford University of School of Medicine. He concurrently completed a postdoctoral fellowship at Stanford University School of Medicine in biomedical informatics, and family medicine research at the University of California, San Francisco, School of Medicine.


AI and Data Science:
Sutter Health

Based in Sacramento, Sutter Health provides coordinated care to more than 3 million Californians. Sutter’s integrated network created a connected model of care that’s delivering accessible & inclusive care when, where & how people need it by tailoring care to the diverse communities we serve.

Improving the Digital Patient Experience During COVID-19 & Beyond
If COVID-19 has a silver lining, it's the rapid adoption of virtual care. While telehealth is not a substitute for in-person care, it’s given us the opportunity to accelerate innovation to personalize care and support better health outcomes for all.

 Session Abstract – PMWC 2022 Silicon Valley


The PMWC 2021 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.